Match Document Document Title
8691945 Antimicrobial peptides  
There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In particular, there is provided a linear analog of hBD3...
8691752 Protein product for treatment of infectious diseases and related inflammatory processes  
The inventors have found that CD6, a member of the Scavenger Receptor Cysteine-Rich (SRSR) superfamily expressed on human lymphocytes binds to Gram-positive and Gram-negative bacteria, as well as...
8691242 Staphylococcus aureus DIV1B for use as vaccine  
The invention relates to an antigenic polypeptide referred to as DivlB and variants thereof, vaccines comprising said polypeptide and the use of the vaccine in protecting subjects from microbial...
8691239 Influenza hemagglutinin and neuraminidase variants  
Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.
8691234 Vaccine formulation potentiated by the combination of DNA and an antigen  
Formulation of vaccine antigens, containing as main components: a—) one or several DNA expressing one or several proteins in the immunized individuals and b—) a viral antigen, in appropriate...
8691235 Absorbable crystalline polyether-ester-urethane-based bioactive luminal liner compositions  
Bioactive hydroforming luminal liner compositions are formed of an absorbable crystalline amphiphilic polyether-ester-urethane dissolved in a liquid derivative of a polyether glycol that undergoes...
8685404 Recombinant T-cell receptor ligand for the treatment of cognitive and neuropsychiatric impairment induced by substance addiction  
Methods are provided for the treatment of subjects with cognitive or neuropsychiatric impairment induced by substance addiction and for increasing cognitive function in a subject with substance...
8685413 Heterologous protection against Pasteurella multocida provided by P. multocida fur cells and the outer-membrane protein extracts thereof  
The invention relates to Pasteurella multocida mutants capable of providing heterologous protection against infection caused by virulent P. multocida . Said mutants are defective in fur ompH and...
8685403 Insulin-like growth factor signaling and integrin  
Interaction between insulin-like growth factor 1 (IGFI) and integrin is involved in integrin-mediated cellular signaling, such as enhanced proliferation of cells expressing integrins, especially...
8685412 Hemorrhagic feline calicivirus, calicivirus vaccine and method for preventing development of calicivirus disease  
The present invention relates to a novel, isolated and purified hemorrhagic feline calicivirus FCV-DD1. The invention further embraces monovalent and multivalent vaccines containing the new...
8685694 Methods and compositions comprising bacteriophage nanoparticles  
Compositions and methods comprising bacteriophages are provided. In particular, the present invention includes novel and customized T4 bacteriophages uniquely designed for effective antigen and...
8685670 Isolated chimeric proteins of modified lumazine synthase  
Isolated chimeric proteins including up to ten copies of peptides, polypeptides or protein domains inserted in the amino termini of the Brucella spp. Lumazine synthase enzyme. Isolated nucleotide...
8679504 Poultry viral materials and methods related thereto  
The present invention provides materials and methods for researching poultry viruses, particularly for researching infectious bronchitis viruses in poultry. Also provided are materials and methods...
8679510 Porin B (PorB) as a therapeutic target for prevention and treatment of infection by Chlamydia  
The present invention features peptides of a PorB polypeptide, which PorB peptides are useful in production of antibodies that bind the full-length PorB polypeptide and as a therapeutic agent. In...
8678184 Methods for producing vaccine adjuvants  
An improved method for the manufacture of an oil-in-water emulsion involves three procedures: (i) preparation of a preliminary emulsion; (ii) microfluidization of the preliminary emulsion to...
8679540 Pharmaceutical formulations for the prolonged release of active principle(s), and their applications, especially therapeutic applications  
The present invention relates to novel pharmaceutical formulations based on aqueous colloidal suspensions for the prolonged release of one or more active principles, and to the applications,...
8679501 Method for modulating inflammatory responses  
The present invention is a method for inhibiting Treg cell functional activities by blocking Treg cell-mediated mast cell activation. It has been found IL-9 produced by Treg cells activates mast...
8673361 Cytokine modulating composition  
The invention relates to an agent having cytokine mediating activity. In particular the invention relates to a composition comprising a fraction of denatured plasma proteins and at least one...
8673293 Use of modified cells for the treatment of multiple sclerosis  
The present invention describes blood cells chemically coupled with immunodominant myelin peptides and their use in the treatment of Multiple Sclerosis.
8673312 Method for one-step purification of recombinant Helicobacter pylori neutrophil-activating protein  
Helicobacter pylori is closely associated with chronic gastritis, peptic ulcer disease, and gastric adenocarcinoma. Helicobacter pylori neutrophil-activating protein (HP-NAP), a virulence factor...
8673318 Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions  
The present invention relates to a method for the cultivation of primary cells. The primary cells are cultivated in a serum free medium comprising a factor selected from the group consisting of...
8673317 Codon-optimized polynucleotide-based vaccines against human Cytomegalovirus infection  
The invention relates to plasmids operably encoding HCMV antigens, in which the naturally-occurring coding regions for the HCMV antigens have been modified for improved translation in human or...
8673311 Bacterial spore having therapeutic agent adsorbed on its surface  
The present invention relates to a method of coating a spore with one or more therapeutic agents. The present invention also relates to a coated spore obtained by the method of the present...
8673289 Attenuated uracil auxotroph of an apicomplexan and use thereof  
Uracil auxotroph mutants of apicomplexans are provided which lack a functional carbamoyl phosphate synthase II (CPSII) enzyme. Also provided are T. gondii autoxtroph mutants which express...
8669237 Biodegradable immunomodulatory formulations and methods for use thereof  
The invention provides new compositions and methods for immunomodulation of individuals. Immunomodulation is accomplished by administration of immunomodulatory polynucleotide/microcarrier (IMP/MC)...
8663644 Augmentation of titer for vaccination in animals  
The disclosure relates to a composition added to animal feed used in combination with a vaccine to enhance the effectiveness of the vaccine. Amongst other effects, the composition raises the titer...
8663650 Methods and compositions comprising supramolecular constructs  
The present invention comprises novel compositions and methods for eliciting high immune responses, of great specifity yielding conformationally sensitive antibodies. These antibodies recognize...
8663657 Nucleic acid constructs  
A nucleic acid construct comprising a chimeric promoter sequence and a cloning site for insertion of a coding sequence in operable linkage with the chimeric promoter, wherein the chimeric promoter...
8663651 T-140 peptide analogs having CXCR4 super-agonist activity for immunomodulation  
The present invention is directed to novel therapeutic uses of T-140 analog peptides and compositions comprising same. Specifically, the invention provides compositions and methods useful for...
8658136 Methods to increase transgene expression from bacterial-based delivery systems by co-expressing suppressors of the eukaryotic type I interferon response  
Bacterial delivery systems with improved transgene expression are provided. The recombinant bacterial delivery systems deliver transgenes of interest and suppressors of the eukaryotic Type I...
8658766 Soluble hybrid Fcγ receptors and related methods  
Disclosed are soluble hybrid Fcγ receptor (FcγR) polypeptide compositions and related methods of using such polypeptides to treat IgG-mediated and immune complex-mediated inflammation. Also...
8658180 Vaccines against influenza virus  
Disclosed are immunogenic conjugates having the general formula: M2e-Cys-S—CH2—C(O)—NH—CH2—CH2-C(O—)NH-Lys-Pr, were M2e is the influenza M2 ectodomain (M2e) peptide; Cys is a cysteine amino acid...
8658592 Biologically active peptides and their new uses  
Novel peptides are disclosed with their use as a pharmaceutical composition. A method is also disclosed for making pharmaceutical compositions and treatment of an individual.
8652481 Mycoplasma bovis vaccine and methods of use thereof  
The present invention relates to new attenuated M. bovis bacteria strains. Moreover, the present invention also provides immunogenic compositions comprising live bacteria of an of those attenuated...
8652482 HPV E6 protein T cell epitopes and uses thereof  
The present invention is directed to the examination of the pattern of immunodominant T cell epitopes in the E6 protein of Human Papilloma virus and its further characterization in terms of its...
8652484 Delivery system for cytotoxic drugs by bispecific antibody pretargeting  
The present invention relates to methods and compositions for pretargeting delivery of therapeutic agents. In preferred embodiments, the pretargeting method comprises: a) administering a...
8652480 Shortened purification process for the production of capsular Streptococcus pneumoniae polysaccharides  
A shortened process for producing a solution containing substantially purified capsular polysaccharides from a cellular Streptococcus pneumoniae lysate broth is described. Ultrafiltering and...
8652487 Tolerogenic synthetic nanocarriers for inducing regulatory B cells  
Disclosed are synthetic nanocarrier methods, and related compositions, comprising B cell and/or MHC Class II-restricted epitopes and immunosuppressants in order to generate tolerogenic immune...
8652489 Therapeutic composition with a botulinum neurotoxin  
The present invention pertains to pharmaceutical compositions which comprise a botulinum neurotoxin from Clostridium botulinum, the neurotoxin being free of the complexing proteins naturally...
8652483 Viral infection enhancing peptide  
The invention relates to a peptide derived from HIV-1 gp120 which forms insoluble aggregates when introduced into an aqueous solution and its use for enhancing viral infection of cells. In...
8647634 Recombinant avian infectious coryza vaccine and process for preparing same  
A recombinant avian infectious coryza vaccine and a process for preparing the same are provided. A process for preparing a recombinant avian infectious coryza vaccine which comprises step of...
8647627 Composition for a cancer vaccine  
Pharmaceutical compositions useful as vaccines are described containing a purified surface or excreted protein qualitatively or quantitatively associated with a type of cancer, at least one...
8647617 Methods for modulating inflammatory and/or immune responses  
The invention is directed to novel methods for modulating inflammatory and/or immune responses. Such methods utilize compositions comprising extraembryonic cells (herein referred to as EE cells)...
8647642 Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment  
Gram-negative bacteria, and compositions containing the bacteria, resistant to one or more stress conditions, including, but not limited to, CO2, acid pH, and high osmolarity, having reduced...
8647636 Low antigen-dose immunization utilizing overlapping peptides for maximizing T-helper cell 1 (Th1) immunity against a pathogen  
Disclosed are compositions, kits, and methods for inducing an immune response against disease. The dosage of antigen contained or utilized in the presently disclosed compositions, kits, and...
8647643 Farnesoid-X-receptor antagonist as a vaccine adjuvant  
The invention provides novel adjuvants and pharmaceutical composition comprising of an adjuvant alone. The invention also provides novel vaccine compositions comprising of an antigen and a novel...
8647628 Peptide epitopes of apolipoprotein B  
The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including...
8647818 Molecular scaffolds for HIV-1 immunogens  
Methods and compositions are provided which employ chimeric polypeptides having at least one heterologous epitope for a human immunodeficiency virus type 1 (HIV-1) neutralizing antibody. These...
8642043 Peptide epitopes of apolipoprotein B  
The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including...
8642042 Protein matrix vaccines and methods of making and administering such vaccines  
The invention relates to vaccine compositions having a carrier protein and an antigen of interest entrapped in a complex, methods of making such vaccines, and methods of vaccine administration.